183 related articles for article (PubMed ID: 28226001)
1. Recombinant human TSH versus thyroid hormone withdrawal in adjuvant therapy with radioactive iodine of patients with papillary thyroid carcinoma and clinically apparent lymph node metastases not limited to the central compartment (cN1b).
Rosario PW; Mourão GF; Calsolari MR
Arch Endocrinol Metab; 2017; 61(2):167-172. PubMed ID: 28226001
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Low-dose and High-dose Radioactive Iodine Ablation With rhTSH in Korean Patients With Differentiated Thyroid Carcinoma: The First Report in Nonwestern Countries.
Joung JY; Choi JH; Cho YY; Kim NK; Sohn SY; Kim SW; Chung JH
Am J Clin Oncol; 2016 Aug; 39(4):374-8. PubMed ID: 24732812
[TBL] [Abstract][Full Text] [Related]
3. Thyroid ablation with 1.1 GBq (30 mCi) iodine-131 in patients with papillary thyroid carcinoma at intermediate risk for recurrence.
Rosário PW; Calsolari MR
Thyroid; 2014 May; 24(5):826-31. PubMed ID: 24283207
[TBL] [Abstract][Full Text] [Related]
4. Comparison of thyroid hormone withdrawal and recombinant human thyroid-stimulating hormone administration for adjuvant therapy in patients with intermediate- to high-risk differentiated thyroid cancer.
Iizuka Y; Katagiri T; Ogura K; Inoue M; Nakamura K; Mizowaki T
Ann Nucl Med; 2020 Oct; 34(10):736-741. PubMed ID: 32643022
[TBL] [Abstract][Full Text] [Related]
5. Day 3 thyroglobulin ≤ 1 ng/ml after recombinant human TSH just prior to radioactive iodine is predictive of low risk for persistent/recurrent disease in patients with papillary thyroid carcinoma.
Rosario PW; Siman TL; Calsolari MR
Endocrine; 2015 May; 49(1):170-4. PubMed ID: 25209895
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human thyrotropin in thyroid remnant ablation with 131-iodine in high-risk patients.
Rosario PW; Xavier AC; Calsolari MR
Thyroid; 2010 Nov; 20(11):1247-52. PubMed ID: 20950256
[TBL] [Abstract][Full Text] [Related]
7. Stimulated thyroglobulin level at ablation in differentiated thyroid cancer: the impact of treatment preparation modalities and tumor burden.
Ciappuccini R; Hardouin J; Heutte N; Vaur D; Quak E; Rame JP; Blanchard D; de Raucourt D; Bardet S
Eur J Endocrinol; 2014 Aug; 171(2):247-52. PubMed ID: 24866576
[TBL] [Abstract][Full Text] [Related]
8. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
[TBL] [Abstract][Full Text] [Related]
9. Is 131I ablation necessary for patients with low-risk papillary thyroid carcinoma and slightly elevated stimulated thyroglobulin after thyroidectomy?
Rosario PW; Mourão GF
Arch Endocrinol Metab; 2016 Feb; 60(1):5-8. PubMed ID: 26909477
[TBL] [Abstract][Full Text] [Related]
10. Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin.
Klubo-Gwiezdzinska J; Burman KD; Van Nostrand D; Mete M; Jonklaas J; Wartofsky L
Thyroid; 2012 Mar; 22(3):310-7. PubMed ID: 22313411
[TBL] [Abstract][Full Text] [Related]
11. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function.
Tuttle RM; Lopez N; Leboeuf R; Minkowitz SM; Grewal R; Brokhin M; Omry G; Larson S
Thyroid; 2010 Mar; 20(3):257-63. PubMed ID: 20187781
[TBL] [Abstract][Full Text] [Related]
12. Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH.
Tala H; Robbins R; Fagin JA; Larson SM; Tuttle RM
J Clin Endocrinol Metab; 2011 Jul; 96(7):2105-11. PubMed ID: 21565788
[TBL] [Abstract][Full Text] [Related]
13. Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial.
Schlumberger M; Leboulleux S; Catargi B; Deandreis D; Zerdoud S; Bardet S; Rusu D; Godbert Y; Buffet C; Schvartz C; Vera P; Morel O; Benisvy D; Bournaud C; Toubert ME; Kelly A; Benhamou E; Borget I
Lancet Diabetes Endocrinol; 2018 Aug; 6(8):618-626. PubMed ID: 29807824
[TBL] [Abstract][Full Text] [Related]
14. Long-term results of ablation with low radioiodine activity in patients with papillary thyroid carcinoma and predictive value of postoperative nonstimulated thyroglobulin.
Rosario PW; Mourão GF; Calsolari MR
Nucl Med Commun; 2016 Oct; 37(10):1024-9. PubMed ID: 27306852
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of adjuvant therapy with 3.7 GBq radioactive iodine in intermediate-risk patients with 'higher risk features' and predictive value of postoperative nonstimulated thyroglobulin.
Rosario PW; Mourão GF; Calsolari MR
Nucl Med Commun; 2016 Nov; 37(11):1148-53. PubMed ID: 27341413
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Outcomes of Patients with Papillary Thyroid Cancer Undergoing Remnant Ablation with 30 milliCuries Radioiodine.
Mujammami M; Hier MP; Payne RJ; Rochon L; Tamilia M
Thyroid; 2016 Jul; 26(7):951-8. PubMed ID: 27150203
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human thyrotropin preparation for adjuvant radioiodine treatment in children and adolescents with differentiated thyroid cancer.
Handkiewicz-Junak D; Gawlik T; Rozkosz J; Puch Z; Michalik B; Gubala E; Krajewska J; Kluczewska A; Jarzab B
Eur J Endocrinol; 2015 Dec; 173(6):873-81. PubMed ID: 26423095
[TBL] [Abstract][Full Text] [Related]
18. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?
Mazzaferri EL; Kloos RT
J Clin Endocrinol Metab; 2002 Apr; 87(4):1490-8. PubMed ID: 11932270
[TBL] [Abstract][Full Text] [Related]
19. Recombinant Thyrotropin vs Levothyroxine Withdrawal in 131I Therapy of N1 Thyroid Cancer: A Large Matched Cohort Study (ThyrNod).
Leenhardt L; Leboulleux S; Bournaud C; Zerdoud S; Schvartz C; Ciappuccini R; Kelly A; Morel O; Dygai-Cochet I; Rusu D; Chougnet CN; Lion G; Eberlé-Pouzeratte MC; Catargi B; Kabir-Ahmadi M; Le Peillet Feuillet E; Taïeb D
J Clin Endocrinol Metab; 2019 Apr; 104(4):1020-1028. PubMed ID: 30398518
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of Papillary Thyroid Microcarcinoma Presenting with Palpable Lateral Lymphadenopathy.
Papachristos A; Do K; Tsang VH; Sywak M; Gill AJ; Sidhu S; Clifton-Bligh RJ; Glover A; Gild ML
Thyroid; 2022 Sep; 32(9):1086-1093. PubMed ID: 35703333
[No Abstract] [Full Text] [Related]
[Next] [New Search]
